Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.

The Lancet. Oncology·2025
Same author

Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer.

Clinical pharmacokinetics·2025
Same author

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Clinical breast cancer·2025
Same author

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE<sup>®</sup>) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.

Clinical pharmacokinetics·2024

Related Experiment Video

Updated: Dec 29, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.7K

Dedifferentiated Liposarcoma: Systemic Therapy Options.

Zhubin Gahvari1, Amanda Parkes2

  • 1University of Wisconsin Carbone Cancer Center, 600 Highland Ave, Madison, WI, 53792, USA.

Current Treatment Options in Oncology
|February 7, 2020
PubMed
Summary
This summary is machine-generated.

The treatment for dedifferentiated liposarcoma (DDLPS) has advanced beyond traditional chemotherapy. New targeted therapies and immunotherapies are showing promise, expanding options for patients with advanced disease.

Keywords:
CDK4ChemotherapyDedifferentiated liposarcomaLiposarcomaMDM2Metastatic

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

Related Experiment Videos

Last Updated: Dec 29, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.7K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

Area of Science:

  • Oncology
  • Medical Science

Background:

  • The systemic treatment for dedifferentiated liposarcoma (DDLPS) has historically relied on cytotoxic chemotherapy.
  • Limited efficacy and toxicity of older agents necessitated exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review the evolving systemic treatment landscape for dedifferentiated liposarcoma (DDLPS).
  • To discuss recent advances in targeted therapies and immunotherapies for advanced DDLPS.
  • To highlight ongoing research and future directions in DDLPS treatment.

Main Methods:

  • Review of recent phase II and III clinical trials.
  • Analysis of investigational targeted therapies based on DDLPS molecular biology (MDM2, CDK4).
  • Evaluation of immunotherapy agents and their potential combinations.

Main Results:

  • Established clinical benefit of trabectedin, eribulin, and pazopanib in advanced liposarcoma and DDLPS.
  • Clinical trials support CDK4 inhibitors (abemaciclib) and nuclear export inhibitors (selinexor).
  • Anti-MDM2 therapies show promise but face challenges with bone marrow toxicity.

Conclusions:

  • The systemic treatment for DDLPS has significantly expanded with new cytotoxic, targeted, and investigational agents.
  • Further research is needed to optimize combinations, compare therapies, and evaluate roles in localized DDLPS.